GTC Biotherapeutics (fka GTCB)

[DewDiligence]

In the interests of equal time… Artisan Pharma’s phase-2 trial in DIC/sepsis, which has been discussed on this board from time to time, is now open for enrollment at five US sites. (‘Rajuramas’ noted this trial’s listing on clinicaltrials.gov in June, but the trial was not yet open for enrollment at that time.)

http://www.clinicaltrials.gov/ct/show/NCT00487656

ART-123, the product candidate Artisan is developing for DIC, is not antithrombin; rather, it is thrombomodulin, a different molecule in the anticoagulation cascade that increases the inhibitory effect of antithrombin on thrombin.